Skip to search formSkip to main contentSkip to account menu

elbasvir / grazoprevir

Known as: ELBASVIR/GRAZOPREVIR, elbasvir and grazoprevir 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Doravirine is a non-nucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus type 1 (HIV-1… 
2019
2019
Background/Aims In the Republic of Korea, an estimated 231,000 individuals have chronic hepatitis C virus (HCV) infection. The… 
2019
2019
Despite highly effective direct‐acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection, some patients… 
2019
2019
The role of ribavirin (RBV) in the era of direct‐acting antivirals (DAA) is not clear, and DAA studies have been largely genotype… 
2018
2018
Background and ObjectiveNew direct-acting antivirals (DAAs) have high efficacy and tolerability in the treatment of hepatitis C… 
2018
2018
Treatment with all‐oral direct‐acting antiviral agents (DAAs) elbasvir/grazoprevir (EBR/GZR) is associated with high sustained… 
Highly Cited
2017
Highly Cited
2017
BACKGROUND & AIMS Persons with hepatitis C virus (HCV) infection are at risk of progressive liver disease, cirrhosis, and… 
2017
2017
Among patients with chronic kidney disease (CKD) in the United States, HCV infection causes significant morbidity and mortality…